Sir,

By this correspondence, we wish to emphasise that fluorescein dye toxicity, though rarely noticed and usually a diagnosis of exclusion is quite dangerous. Therefore, it should be used in dilute concentrations, after appropriate consent with proper documentation of baseline neurologic status and proper postoperative monitoring of the patient. A 35-year-old, 70-kg male with left cerebrospinal fluid otorrhoea was posted for repair of the leak under general anaesthesia. There was no history of any comorbidity preoperatively. Left myringotomy and grommet insertion had been done for serous otitis media under local anaesthesia 5 days ago following which the patient developed clear watery discharge from the left ear. The patient had presented with complaints of tinnitus and hearing loss in the left ear after a road traffic accident 4.5 years back when he had suffered a left temporal bone fracture. After smooth anaesthesia induction and surgical antibiotic prophylaxis with intravenous (iv) injection (inj) ceftriaxone 2 g, diluted fluoroscein dye (0.5 mL of 10% fluoroscein diluted in 9.5 mL of cerebrospinal fluid) was injected over 10 min in the subarachnoid space through a lumbar puncture to aid in localisation of the site of leak. The surgery lasted for 2.5 h and was uneventful. He was observed in the recovery room for an hour and then shifted to the ward with stable vitals and postoperative orders of nil per oral for 6 h and on iv fluids -- normal saline at 100 mL/h and inj diclofenac 75 mg iv as and when required for analgesia. Two hours post surgery, the patient had three generalised tonic--clonic seizures which subsided with iv midazolam 2 mg. The patient was shifted to the intensive care unit in the post-ictal state with heart rate of 120/min, blood pressure of 90/50 mmHg, respiratory rate of 20/min, saturation (on oxygen by face mask) of 99% and blood sugar levels of 117 mg/dL. Inj levetiracetam 1 g and inj hydrocortisone 100 mg iv were given. Another lumbar puncture was done and cerebrospinal fluid (CSF) was sent for routine microscopy and culture to rule out meningitis. He was hydrated with normal saline boluses, and iv antibiotic 2 g ceftriaxone and 1 g vancomycin were given. Arterial blood gas was done to rule out any metabolic cause. After 2 h, he became fully conscious and oriented with stable haemodynamics. Magnetic resonance imaging brain with contrast was normal. CSF picture was nonmeningitic. He was seizure-free thereafter and was discharged after 2 days. It was concluded that the seizures occurred because of fluorescein toxicity.

The intrathecal sodium fluorescein is useful in localising the defect in CSF leak.\[[@ref1][@ref2][@ref3]\] Fluorescein toxicity may present as headache, paresthesias, seizures and vomiting.\[[@ref1][@ref4][@ref5]\] Severe complications such as epileptic crisis, grand mal epilepsy, opisthotonous and peripheral nerve palsy are always secondary to use of higher concentrations.\[[@ref2]\] The etiology is unclear, but it may be the direct irritant action of fluorescein by way of chemical meningeal irritation.\[[@ref6]\] These complications from intrathecal application of fluorescein are usually dose-dependent. Decreased incidence of complications is noted with careful lumbar puncture and slow intrathecal administration of very low doses of 0.1--0.25 mL of 10% fluorescein.\[[@ref1][@ref2][@ref5]\] The side effects are rare and transient with dilute concentrations. The onset time may vary from 30 min to 12 h after the injection.\[[@ref6]\] The patient should be supervised for 24 h and a written informed consent from patients for the use of fluorescein is recommended.\[[@ref1][@ref5]\] Premedicating the patient with steroids and antihistamines may diminish the risk.\[[@ref2]\] Seizures can be treated with iv benzodiazepines or barbiturates.\[[@ref6]\] At our institute, we were using 0.5 mL of 10% (50 mg) fluoroscein, but now we use 0.1 mL of 10% (10 mg) fluorescein diluted in 10 mL of CSF, which is injected slowly over 10 min. This has resulted in increased safety margin without loss of diagnostic advantage.
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